
Diana Mitrea
@diamitrea
ID: 1507422959236964363
25-03-2022 18:26:20
79 Tweet
87 Followers
86 Following

In a recent Pharmafocus interview, Dewpoint CEO Ameet Nathwani shares his thoughts on the current landscape of diabetes therapies. Read to learn how #condensates play a role in disease progression and may be targeted with a new generation of therapeutics: pharmafocus.com/collections/ph…


Published today in Nature Communications - our efforts to better understand the prevalence of biomolecular condensate formation amongst fusion oncoproteins found in a range of diverse cancers. rdcu.be/dneM5


Dewpoint co-founder Richard Young, board member Regina Barzilay, head of Cancer Biology Ann Boija & team published in Nature Chemical Biology how deep learning predicts specific partitioning of small molecules in #condensates with distinct chemical environments: nature.com/articles/s4158…

In the last 5 years, Dewpoint has made huge progress evolving and applying the science of condensates towards therapeutic discovery. Read our latest article to hear more from our CSO Isaac Klein bit.ly/45YJ9mn




We are pleased to share Dewpoint CSO Isaac Klein’s Drug Discovery World podcast about the intersection of #condensate science and therapeutic development. Isaac brings his unique perspective as a physician-scientist to solving complex biological puzzles and advancing drug discovery.

Read our latest Journal of Molecular Biology perspective by Erik Martin, Christiane Iserman, Balaji Olety, Diana Mitrea & Isaac Klein reviewing the role of #condensates in the viral replication cycle and discussing novel strategies to target them for novel antiviral therapies: sciencedirect.com/science/articl…

Our newest perspective discussing opportunities in targeting #condensates as a new class of antivirals is now in press Journal of Molecular Biology with Dewpoint Therapeutics


Don't miss Drago Milovanovic 's upcoming Kitchen Table Talk, on October 30th! Registration is open at condensates.com





Great coverage in The Pharma Letter about a major milestone for Dewpoint – the nomination of our first development candidate, DPTX3186, as a potential therapeutic agent for the treatment of Wnt-driven cancers. Read the article: thepharmaletter.com/major-mileston…

Our lab's latest News & Views in Nature Chemistry analyzes key findings from Thody et al: physicochemical properties, not structure, drive small molecule partitioning into biomolecular condensates. Important implications for drug development! Kriwacki Lab nature.com/articles/s4155…

